CompletedNot Applicable

Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy

China442 participantsStarted 2024-06-10

Plain-language summary

HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic stratification and tumor treatment response prediction.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * (1) AGC with clinical stage T2-4NxM0 (cT2-4NxM0) before NAT, (2) no history of other malignant tumors, distant metastases or invasion of adjacent organs, and (3) patients who underwent radical gastrectomy after receiving NAT. Exclusion Criteria: * (1) history of upper abdominal surgery (except for the laparoscopic cholecystectomy), (2) history of upper abdominal radiotherapy, (3) emergency surgery, or palliative surgery, (4) continuous use of medications such as anticoagulant, antiplatelet, and leukocyte-boosting drugs that significantly affect hematological markers during therapy, and (5) incomplete clinical and follow-up data.

What they're measuring

3-year OS

Timeframe: 3-year OS or 36 months

3-year DFS

Timeframe: 3 years DFS or 36 months

Tumor Regression Grade

Timeframe: 3 years or 36 months

Trial details

NCT IDNCT06573307

SponsorChang-Ming Huang, Prof.

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-10

View on ClinicalTrials.gov More Gastric Cancer trials